hrs4r
Quiero donar

EUGENI LÓPEZ BONET

Firma
EUGENI LÓPEZ-BONET
Posición
Investigadors/es Col·laboradors/es
Investigadores/as Colaboradores/as

Projectes

Codi oficial: La Marató 201912-31 Data inicio:30/09/2020 Data fi: 31/01/2024 Investigador/a principal: XAVIER ALDEGUER MANTE Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 199,812.50 €
Codi oficial: IMPROSA Data inicio:01/04/2022 Data fi: 30/06/2023 Investigador/a principal: ERNESTO BARZOLA NAVARRO Organisme finançador: F. ASOC. ESP. COLOPROCTOLOGIA Ajuda: 6,600 €

Publicacions

0

Prognostic significance of the microbiome-adipose tissue axis in rectal cancer: protocol of a prospective observational study

BJS Open, 2022, 6 dx.doi.org/10.1093/bjsopen/zrac009

Temprana-Salvador J, López-García P, Castellví Vives J, de Haro L, Ballesta E, Rojas Abusleme M, Arrufat M, Marques F, Casas JR, Gallego C, Pons L, Mate JL, Fernández PL, López-Bonet E, Bosch R, Martínez S, Ramón Y Cajal S, Matias-Guiu X

DigiPatICS: Digital Pathology Transformation of the Catalan Health Institute Network of 8 Hospitals-Planification, Implementation, and Preliminary Results.

Diagnostics, 2022, 12 dx.doi.org/10.3390/diagnostics12040852

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168

Sanvisens A, Puigdemont M, Rubió-Casadevall J, Vidal-Vila A, López-Bonet E, Martín-Romero F, Marcos-Gragera R

Differences in the Impact of COVID-19 on Pathology Laboratories and Cancer Diagnosis in Girona

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 dx.doi.org/10.3390/ijerph182413269

Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, Bosch-Barrera J, Encinar JA, Menendez JA

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity

Aging-Us, 2020, 12, 8-34 dx.doi.org/10.18632/aging.102646

Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Journal of Clinical Medicine, 2019, 8 dx.doi.org/10.3390/jcm8122180

Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

Aging-Us, 2019, 11, 2874-2888 dx.doi.org/10.18632/aging.101960

Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

Frontiers in oncology, 2019, 9, 193-193 dx.doi.org/10.3389/fonc.2019.00193

Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.

Oncotarget, 2018, 9, 35687-35704 dx.doi.org/10.18632/oncotarget.26286

Puig-Costa M, Codina-Cazador A, Cortés-Pastoret E, Oliveras-Ferraros C, Cufí S, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Corominas-Faja B, Cuyàs E, Ortiz R, Lopez-Bonet E, Queralt B, Guardeño R, Martin-Castillo B, Roig J, Joven J, Menendez JA

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.

Oncotarget, 2014, 5, 1942-1954 dx.doi.org/10.18632/oncotarget.1879

Formulari de contacte

Conoce el IDIBGI!

menu